Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy.

Giovanni Cuda(National Institutes of Health), Nava Epstein(Sheba Medical Center), James R. Sellers(National Heart Lung and Blood Institute), Lameh Fananapazir(National Heart Lung and Blood Institute), Wahwah Zhu(National Institutes of Health)
Journal of Clinical Investigation
June 1, 1993
10.1172/jci116530
Cited by 242

Related Papers

Mechanism of Blebbistatin Inhibition of Myosin II
|Journal of Biological Chemistry|2004|1k
Targeted integration of adeno‐associated virus (AAV) into human chromosome 19.
|The EMBO Journal|1991|774
Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.
|Circulation|1994|383
Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation.
|Circulation|1992|230
Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations.
|Circulation|1994|226